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Neurofibromatosis type I 
ABSTRACT 11 
Pediatric spinal oligodendrogliomas are rare and aggressive tumors. They do not share the 12 
same molecular features of adult oligodendroglioma, and no previous reports have examined the 13 
molecular features of pediatric spinal oligodendroglioma. We present the case of a child with a 14 
recurrent spinal anaplastic oligodendroglioma. We performed whole exome (paired tumor and 15 
germline DNA) and transcriptome (tumor RNA) sequencing, which revealed somatic mutations in 16 
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NF1 and FGFR1. This data allowed us to explore potential personalized therapies for this patient and 1 
expose molecular drivers that may be involved in similar cases. 2 
 3 
INTRODUCTION  4 
Spinal cord oligodendrogliomas are very rare tumors, comprising less than five percent of 5 
spinal cord tumors in all ages.1-5 In children, spinal tumors are even less common, with spinal gliomas 6 
accounting for only 1-3.5% of all pediatric CNS tumors; only a few cases and one case series of two 7 
spinal oligodendrogliomas have been reported in the pediatric population.3,5,6 While standard 8 
treatment consists of surgical resection, alkylating chemotherapy, and radiation therapy, there is no 9 
consistently-followed regimen given the rarity of pediatric high-grade spinal oligodendrogliomas.  10 
The field of neuro-oncology is increasingly moving toward personalized treatment options 11 
for patients. The molecular analysis of adult gliomas by numerous investigators has resulted in the 12 
identification of several cytogenetic markers that confer varying prognostic benefits and therapeutic 13 
responses.1,7 However, these features (e.g., 1p/19q co-deletion) are less informative in the pediatric 14 
glioma setting.8 Furthermore, the molecular features of pediatric spinal oligodendroglioma 15 
specifically have not previously been examined. We present a case of a child with a spinal anaplastic 16 
oligodendroglioma (AO) and discuss our investigation of potential targeted agents using tumor 17 
sequencing data. 18 
 19 
RESULTS 20 
  A three-year-old female presented with a two-month history of neck pain, left leg weakness, 21 
asymmetric gait, and right head tilt. Spinal MRI revealed a 6 cm x 1 cm enhancing intramedullary 22 
mass extending from C4-T4 (Fig. 1A). She underwent uncomplicated subtotal resection of the 23 
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primary tumor. Total resection was avoided due to intimate involvement of the tumor with the 1 
spinal cord. Her gait had improved by one week after surgery. Pathology revealed a grade III AO with 2 
a Ki-67 tumor cell proliferative index of 10-25%. FISH was negative for 1p/19q co-deletion. She 3 
underwent adjuvant chemotherapy with 18 cycles of oral temozolomide, but when a three-month 4 
surveillance MRI suggested tumor progression, temozolomide was re-initiated for nine additional 5 
cycles. Surveillance MRIs remained stable for three years from discontinuation of chemotherapy, 6 
when she developed progressive neck pain and weakness in both legs. Repeat MRI revealed tumor 7 
progression as an enhancing lesion spanning C5-T2, with a nodular enhancing focus at C4, 8 
progression of edema to C2-C3, and a syrinx from the lower cervical spine to the conus (Fig. 1B).  9 
She underwent subtotal resection of the recurrent tumor and syrinx decompression via 10 
syringo-subarachnoid shunt placement. Lower extremity weakness improved post-operatively with 11 
no new deficits. Recurrent tumor pathology remained AO, with microvascular proliferation and a Ki-12 
67 of 4%, IDH mutation negative, O-6-methylguanine-DNA methyltransferase (MGMT) promoter 13 
unmethylated, ATRX preserved, and p53 not overexpressed (Figs. 1C and 1D). Restaging studies with 14 
brain MRI and CSF cytologic analysis were unremarkable. Total spine MRI two weeks after surgery 15 
showed decreased size of the syrinx and stable residual tumor. She underwent conformal proton 16 
radiotherapy with 50.4 GyE to the resection bed and vertebral bodies, but she subsequently 17 
developed acute radiation necrosis and back pain, which has responded well to steroids and 18 
bevacizumab.  19 
At the time of recurrence, the patient was enrolled on PEDS-MIONCOSEQ, a precision 20 
oncology study involving whole exome (paired tumor and germline DNA) and transcriptome (tumor 21 
RNA) sequencing. Clinically-integrated sequencing was performed according to previous published 22 
methodology.9 Nucleic acid preparation, high-throughput sequencing, and computational analysis 23 
were performed using standard protocols in our sequencing laboratory in the Michigan Center for 24 
Translational Pathology, which adheres to the Clinical Laboratory Improvement Amendments (CLIA). 25 
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Sequencing revealed a somatic point mutation and three small deletions in NF1, consistent 1 
with biallelic inactivation (Supplementary Table S1). There was no evidence of germline NF1 2 
alterations, skin lesions, or family history suggestive of Neurofibromatosis type I (NF1). Sequencing 3 
also revealed two somatic activating missense mutations in FGFR1 (Supplementary Table S2). No 4 
mutations in BRAF were observed, which are recurrently found in some oligodendrogliomas.10 5 
Sequencing results were otherwise unremarkable (Supplementary Fig. S1). Results of her tumor 6 
sequencing were discussed in our multidisciplinary CNS precision medicine tumor board – 7 
teleconferenced with clinicians at multiple children’s hospitals – which recommended adjuvant 8 
therapy with a fibroblast growth factor receptor (FGFR) inhibitor and/or a MAPK/ERK Kinase (MEK) 9 
inhibitor, although she was not eligible for any clinical trials using these agents at that time. Therapy 10 
with the FGFR inhibitor ponatinib (off-study) is planned as a maintenance therapy upon clinical 11 
improvement. 12 
13 
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DISCUSSION: 1 
The prognosis for pediatric high-grade gliomas (HGG) remains dismal despite multimodal 2 
treatment approaches, and the few reports on outcomes for spinal cord HGG’s are also 3 
discouraging.5,11,12 High-grade oligodendrogliomas in any location are uncommon in children and 4 
have unfavorable outcomes as well.4,11,12 Only four AO’s were confirmed among 250 HGG patients 5 
treated on the CCG-945 Children’s Cancer Study Group clinical trial, and four non-6 
glioblastoma/anaplastic astrocytomas were observed among 107 patients with HGG treated on the 7 
ACNS0126 Children’s Oncology Group trial.11,12 Lundar et al. followed 35 children with cerebral 8 
oligodendrogliomas and found five- and 10-year overall survival of only 27% and 18%, respectively, 9 
for the anaplastic tumors.4 The prognosis of the very few reported pediatric spinal AO is also poor; 10 
Merchant et al. reported 2 patients with AO among 11 high-grade pediatric spinal tumor patients 11 
who survived only 29 and 39 months, respectively.5 12 
The molecular features of adult oligodendroglioma are well described. 1p/19q co-deletion is 13 
found in 50-70% of adult gliomas and confers an improved response to chemotherapy and overall 14 
survival.1,7 However, this high frequency and survival benefit for co-deletion has not been shown in 15 
pediatric gliomas.4,8,12,13 Similarly, methylation of the MGMT promoter and IDH1 mutations are only 16 
rarely seen in pediatric HGG.14 While these markers are helpful in guiding adult oligodendroglioma 17 
therapy, new molecular markers are needed for management of pediatric oligodendroglioma. 18 
Molecular analysis of our patient’s tumor displayed NF1 loss-of-function mutations FGFR1 19 
activating mutations. Mutations in the tumor suppressor gene NF1 are classically associated with 20 
NF1, a germline disorder characterized by neurofibromas, malignant peripheral nerve sheath tumors 21 
(MPNST’s), optic pathway gliomas, and cutaneous findings.15 NF1 codes for neurofibromin, which 22 
promotes inactivation of Ras, downregulating the Ras-Mitogen-activated protein kinase (MAPK) 23 
pathway.16 Loss-of-function mutations in neurofibromin result in up-regulation of the Ras-MAPK 24 
pathway and increased cellular proliferation. Sporadic, NF1 somatic mutations have been observed 25 
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by sequencing in many tumor types.17 Interestingly, patients with a diagnosis of NF1 (germline NF1 1 
loss) have a slightly higher incidence of intramedullary spinal tumors.18 This raises the question of 2 
whether glial precursor cells in the spine are predisposed to malignant transformation with NF1 loss, 3 
whether somatic or germline. 4 
The FGFR family is comprised of five receptor tyrosine kinases that function in wound 5 
healing, angiogenesis, and cellular proliferation through their interaction with fibroblast growth 6 
factors.19 FGFR1 interfaces with several pathways, including Ras-MAPK.19 Sporadic FGFR1 mutations 7 
have been observed in many tumor histologies, including two medulloblastoma, one low-grade 8 
glioma, and three glioblastoma cases.17 9 
Given the lack of known effective therapies for the recurrent spinal AO in this child and the 10 
molecular leads to the oncogenesis of her tumor from the sequencing, targeted therapies are a 11 
consideration. In particular, inhibition of the Ras-MAPK pathway could be accomplished at the sites 12 
of both observed somatic mutations (Fig. 2). This could be done upstream via FGFR1 inhibition (e.g., 13 
ponatinib), or downstream via MEK inhibition (e.g., trametinib, which is actively being studied in 14 
other NF1-deficient tumors).20  15 
Given that 64% of the sequenced tumor fraction expressed an FGFR1 mutation and only 20% 16 
expressed alterations in NF1, we will initiate ponatinib for this patient. Ponatinib displays moderate 17 
CNS penetration and has published use in the pediatric population.21 Future combination therapy 18 
with trametinib will be considered if the patient tolerates ponatinib therapy and does not display 19 
objective response.  Response will be assessed by determining if the patient shows reduction in 20 
tumor size on surveillance brain imaging (a decrease of <25% of the largest diameters of measurable 21 
lesions and no evidence of new lesions) and remains without worsening tumor-related symptoms. 22 
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 In conclusion, we report genomic data for a case of pediatric spinal AO, a rare and aggressive 1 
tumor. The targetable mutations discovered in this child’s tumor point to potential personalized 2 
therapies for her, and suggest molecular drivers that may be involved in similar cases.  3 
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LEGENDS: 20 
Figure 1: Spinal Oligodendroglioma Imaging and Pathology 21 
1A) Spinal MRI, sagittal image, T1 series post-contrast, illustrating tumor after initial 22 
resection. 1B) Spinal MRI, sagittal image, T1 series post-contrast, showing recurrent disease in the 23 
cervical spine, primarily in the C4-T2 region. 1C) Tumor parenchyma shows histologic findings on 24 
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hematoxylin and eosin stain consistent with grade III anaplastic oligodendroglioma: focal high 1 
density of round to spindled cells; many cells with perinuclear halos; scattered dark and angulated 2 
anaplastic nuclei; two large areas of microvascular proliferation at the left side of the figure; and 3 
microcysts filled with mucin are prominent near the lower right corner of the figure. 1D) ATRX 4 
protein is preserved in nuclei of vascular cells and neoplastic cells (ATRX loss is frequently seen in 5 
ATRX-mutated astrocytoma). 6 
 7 
Figure 2: Proposed Targeted Inhibitors of the Ras-MAPK Pathway 8 
 Neurofibromin loss-of-function and FGFR1 activation in this tumor are the two identified 9 
potential drivers of oncogenesis, and inhibitors of either pathway are attractive targeted therapy 10 
agents. Upstream inhibition of the Ras-MAPK pathway at the level of FGFR1 can be achieved with 11 
the tyrosine kinase inhibitor, ponatinib. Downstream inhibition of the Ras-MAPK pathway can be 12 
achieved with the MEK inhibitor, trametinib. 13 
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Supplementary Figure S1: Tumor Copy Number Profile and LOH Plot 1 
Copy number profile revealed no remarkable change in the genome, with absence of copy 2 
gains, copy losses, and copy neutral loss of heterozygosity (LOH). 3 
 4 
Supplementary Table S1: Sequence Analysis—Observed Mutations and Indels 5 
 Somatic mutations and insertions/deletions observed for FGFR1 and NF1 on chromosomes 8 6 
and 17, respectively, are presented.  32% of the tumor variant fraction contained a TTTCTA base 7 
change in the FGFR1 gene, and 10% of the tumor variant fraction contained a CG base change in 8 
the NF1 gene. Additionally, in NF1, a frameshift deletion and two non-frameshift deletions were 9 
observed at 3%, 2%, and 3% tumor variant frequency, respectively. 10 
Abbreviations: AA: Amino Acid; FPKM: Fragments Per Kilobase of transcript per Million 11 
mapped reads; COSMIC: Catalogue of Somatic Mutations in Cancer; fs: frameshift, del: deletion. 12 
 13 
Supplementary Table S2: Sequence Analysis Summary 14 
Notable mutations were observed in FGFR1 and NF1, amounting to probable biallelic 15 
inactivation of NF1 and activation of the FGFR1 protein, but otherwise no remarkable genomic 16 
changes or germline findings were observed. 17 
